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Abstract
Background: Many reports had been received on the application of antifibrinolytic medications on spinal corrective
surgery and the surgical outcome evaluations of its efficacy on reducing blood loss. This study aimed to assess the
efficacy of tranexamic acid (TXA) in reducing operative blood loss during posterior spinal fusion for the treatment of
severe adolescent idiopathic scoliosis (AIS).
Methods: A retrospective cohort study was carried out on 90 (TXA = 55, Control = 35) AIS girls undergoing posterior
spinal surgery. Patients in TXA group used TXA as an antifibrinolytic agent to reduce blood loss, while control group did
not. Blood loss, haemoglobin change and amount of blood transfused was estimated from intraoperative measurement
by anaesthesiologists. Demographics were compared using Student’s T-test or Chi-square test where appropriate. Linear
regression modelling was carried out between the use of TXA and total blood loss with controlling of confounding
factors.
Results: Mean age and mean maximum major curve were 15.2 and 73°, and 15.3 and 63° in TXA and control groups
respectively. TXA group showed significantly less intra-operative blood loss than the control group from intraoperative
measurement (1.8 L vs. 3.9 L, p < 0.01) and volume of cell saver blood transfused back to patients (0.6 L vs. 1.7 L, p < 0.01).
TXA group also showed significantly shorter total time taken for surgery (437 min vs. 502 min, p< 0.01), and total blood
loss per surgical segment level (0.1 L vs. 0.3 L, p< 0.01). Regression models showed that the use of TXA decreased total
blood loss by 794.3 ml after adjusting for maximum major curve, age, number of segments fused, bone graft, clotting
capability, and infusion of coagulation factors.
Conclusions: Patients undergoing posterior spinal corrective surgery with the use of TXA showed much reduced total
blood loss, reduced use of transfused blood, much less cell saver blood transfused back to the patient. The total blood
loss was decreased by after using TXA after controlling for maximum major curve, age, surgical parameters, clotting
capability, and infusion of coagulation factors.
Keywords: Use of tranexamic acid at surgery in AIS
Background
Reconstructive spinal surgeries have been associated with
large blood losses which is a common potential cause of
morbidity and could subject to known risk of blood trans-
fusions including blood-borne disease transmission, in-
creased incidence of wound infections, haemolytic and
nonhaemolytic transfusion reactions. Despite interven-
tions such as proper patient positioning on the operating
room table, pharmaceutical muscle paralysis to decrease
intra-abdominal pressure, intraoperative blood salvaging,
and controlled hypotensive anaesthesia, blood losses of up
to 3 l can still be expected during some frequently per-
formed procedures in spinal surgeries [1–4]. Therefore,
any reduction in blood loss and the requirement for pa-
tient exposure to homologous blood products would be
beneficial.
* Correspondence: bobng@ort.cuhk.edu.hk
1Department of Orthopaedics & Traumatology, Chinese University of Hong
Kong, Shatin, Hong Kong
3Department of Orthopaedics and Traumatology, The Chinese University of
Hong Kong, Prince of Wales Hospital, Shatin, N.T., Hong Kong
Full list of author information is available at the end of the article
© 2015 Ng et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ng et al. Scoliosis  (2015) 10:28 
DOI 10.1186/s13013-015-0052-9
Since the 1990s, intraoperative administration of antifi-
brinolytics (tranexamic acid, aprotinin, and e-aminocaproic
acid) has gained popularity [5–13]. Antifibrinolytic medica-
tions have been applied during cardiac, total joint arthro-
plasty, and spine surgery with positive effect on blood loss
without apparent increase in the risk of postoperative com-
plications as shown by previous studies [7, 10, 12, 14–16].
Tranexamic acid (trans-4-aminomethyl-cyclohexane-1-car-
boxylic acid, TXA) is a synthetic lysine analogue and exerts
its antifibrinolytic effect through the reversible blockade of
lysine binding sites on plasminogen molecules. TXA is
similar to e-aminocaproic acid but is considered to have 6
to 10 times of the potency in-vitro and has been used quite
successfully in different surgical procedures to reduce op-
erative blood loss [17].
Reconstructive spinal surgeries have been associated
with significant blood loss which is a cause of morbidity.
Previous studies reported antifibrinolytic medications
could help reduce blood loss during surgery [5, 18, 19].
A recent study on the use of TXA in surgical paediatric
patients cohered the results from previous studies on
the significant blood loss reduction after using TXA as
antifibrolytic agent [20]. However, there is still no report
on the possible factors affecting the total blood loss
apart from using TXA. The understanding the possible
factors, apart from the use of TXA, provides very useful
information on other components which could further
control the amount of total blood loss at surgery. This
study aimed to assess the efficacy of tranexamic acid
(TXA) in reducing operative blood loss during posterior
spinal fusion for the treatment of severe adolescent idio-
pathic scoliosis (AIS).
Methods
A retrospective cohort study was carried out on 90 female
adolescents of 10 to 23 years old all undergoing posterior
spinal fusion (PSF) procedures at an institution from year
2005 to 2010. They were recruited on a blind selection
basis consecutively. Patients’ drug allergy history to TXA
was the only contraindication to its use. Otherwise, there
was no other contraindication for any patients in receiving
TXA. Patients who received intraoperative TXA were cat-
egorized into “TXA” group (N = 55), and “Control” group
for non-receivers (N = 35). All patients showed normal
blood urea nitrogen, blood creatinine level, bleeding time,
prothrombin time (PT), activated partial thrombin time
(APTT), international normalized ratio (INR), and serum
platelet concentration. Patients with congenital scoliosis
or neuromuscular disease or with combined anterior and
posterior spinal fusions were excluded. Ethical approval
was obtained from the ethics review board of the joint
NTEC/CUHK joint-institutional ethics committee.
All patients underwent posterior spinal fusion (PSF)
procedures with pedicle screw fixation after general
anaesthesia by a skilled anaesthesiologist. The induction
and maintenance of the general anaesthesia was accom-
plished using standard agents. All TXA group patients re-
ceived an intravenous loading dose of 100 mg/kg TXA
followed by a maintenance dose of 10 mg/kg/h, adminis-
tered until the skin closure. No patient received pre-
operative auto pre-donation, intraoperative administration
of TXA or other anti-fibrinolytics in the control group.
No drain was inserted at the end of the surgical proced-
ure. During the procedures, a special frame which de-
creased intra-abdominal pressure was used to minimize
blood loss. Spinal cord function was monitored by som-
atosensory- and motor-evoked potentials. All patients re-
ceived either donated blood or blood from cell saver. Post-
operative blood transfusion was given when haemoglobin
level dropped below 8 g/dl.
The blood loss was estimated by anaesthesia technician.
The intraoperative blood loss was derived by measuring
the intraoperative suction drainage and weighing the tapes
and sponges. The basic demographic data, surgical statis-
tics, blood loss, clotting capability and infusion of coagula-
tion factors of the two groups were compared by Student’s
T-test. Sensitivity analysis on regression models was car-
ried out to look for the possible risk factors (clotting cap-
abilities, infusion of coagulation factors) affecting the total
blood loss after controlling for confounding factors e.g.,
age at surgery, maximum major curve, number of seg-
ments fused, use of bone graft, length of surgery. Data
analysis were carried out by IBM SPSS 20.0 (Armonk,
New York). A two-sided p value ≤ 0.05 was considered sta-
tistically significant.
Results
This is a retrospective cohort study on 90 (TXA = 55,
Control = 35) female patients aiming to look for the ef-
fect of the use of tranexamic acid on controlling blood
loss in spinal corrective surgery in AIS. There were no
significant differences between the TXA and control
group in age (15.16 vs. 15.31; p = 0.80), mean body
weight (Pre-op: 45.25 kg vs. 42.88 kg, p = 0.20; Post-op:
44.49 kg vs. 43.39 kg, p = 0.65), though the TXA group
had a higher pre-operative major curve (73.42 vs. 63.23;
p = 0.01) (Table 1). TXA group had significantly less
intra-operative blood loss (53.0 % reduction) than the
control group from the estimation by anaesthesia techni-
cian (1.8 L vs. 3.9 L; p < 0.01) (Table 2). Patients in the
TXA group also received a significantly less volume of
salvaged blood from cell saver (0.6 L vs. 1.7 L; p < 0.01).
Different regression models were designed trying to ex-
plain the use of TXA on reducing the total blood loss after
controlling for different kinds of confounders (Table 3).
The statistical significances existed after controlling for
possible confounding factors (age at surgery, number of
segments fused, maximum major curve, use of bone graft,
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and length of surgery), without (model 1 to 4) or with
(model 5 to 8) the clotting capabilities. The best model
(model 6) explained that the use of TXA significantly de-
creased total blood loss by 794.3 ml (r2 = 0.46, B = −5.25,
p < 0.01) after controlling for maximum major curve and
other clinical factors, clotting capabilities, and infusion of
coagulation factor. There were no hemodynamic distur-
bances, apparent thromboembolic complications, or other
drug complications associated with its use, such as dis-
turbed colour vision, numbness or weakness, confusion,
or allergic reactions major intraoperative complications
for any of the treatment groups. No patient had clinical
signs of deep venous thrombosis or renal complications.
Discussion
Pharmacological therapies are commonly used to reduce
blood loss and blood transfusions in surgery. Tranexamic
acid or TXA was previously shown to be as effective as
other antifibrinolytics but at a much lower cost [21, 22].
The safety and efficacy of TXA are still controversial
probably due to the difference in the dose of TXA used
and type of surgery [21, 23]. In this retrospective study,
it was shown that TXA could significantly reduce blood
loss with up to 53.0 % reduction which is in concord-
ance with some similar studies [19, 24, 25]. Intraopera-
tive estimated blood loss was shown to be decreased by
56.8 % for patients using TXA, reported from a com-
parative analysis of 106 consecutive adolescents under-
going PSF in Japan [14]. Moreover, contributing factors
that could alter blood loss were included in regression
analysis, thus proving the efficacy of TXA in reducing
blood loss even after adjustment with possible con-
founding factors, clotting capabilities and infusion of co-
agulation factors. All the patients in this study showed no
Table 1 Baseline characteristics of surgical patients with or without the use of TXA during surgery
Demographics Tranexamic acid P
TXA (N = 55) Control (N = 35)
Age
Mean ± SD (Range) 15.16 ± 2.61 (10–21) 15.31 ± 2.97 (11–23) 0.80
≥ 12 11 (20.0) 4 (11.4) 0.32
13–14 13 (23.6) 15 (42.9)
15–16 11 (20.0) 4 (11.4)
17–18 15 (27.3) 8 (22.9)
≥ 19 5 (9.1) 4 (11.4)
Max major curve (Pre-op) 73.42 ± 11.75 63.23 ± 17.20 <0.01
Body weight (kg)
Pre-op 45.25 ± 8.96 42.88 ± 7.76 0.20
Post-op 44.49 ± 8.14 43.39 ± 8.88 0.65
Armspan (cm)
Pre-op 157.04 ± 8.99 158.32 ± 9.83 0.54
Post-op 156.04 ± 9.40 158.79 ± 9.23 0.35
Body height (cm)
Pre-op 154.01 ± 9.33 155.36 ± 7.70 0.48
Post-op 156.83 ± 9.88 157.76 ± 8.82 0.73
BMI (kg/m2)
Pre-op 19.03 ± 3.53 17.76 ± 3.00 0.08
Post-op 18.07 ± 2.77 17.47 ± 3.28 0.48
Number of segments fused 13.51 ± 1.62 12.14 ± 2.79 0.01
Number of pedicle screws inserted 16.15 ± 2.17 16.29 ± 4.34 0.87
Bone graft
Allograft 1 (2.0) 8 (28.6) <0.01
Autograft/Both 49 (98.0) 20 (71.4)
Unknown 5 7
Length of surgery 436.71 ± 122.53 502.14 ± 85.81 <0.01
TXA tranexamic acid used, Control none used
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severe complications which demonstrated the safety of
TXA.
The use of TXA in major paediatric surgery was
proven to be better than the other commonly used anti-
fibrinolytic agents e.g., aprotinin and aminocaproic acid
[20, 21, 23, 26]. Results from a recent randomized double-
blinded pilot study studying the efficacy of aminocaproic
acid versus TXA in paediatric spinal deformity surgery
concluded that TXA was associated with a lower allogenic
transfusion requirement, less alteration in postoperative
clotting studies, and a trend toward lower blood loss in
paediatric posterior spinal fusion patients [24]. The cost of
TXA is higher than aminocaproic acid, therefore, the use
of TXA is excellent for long and complex surgeries e.g.,
scoliosis and surgeries with the use of autograft and long
fusion levels [27]. Aprotinin was associated with severe side
effects e.g., myocardial infraction, heart failure, and renal
failure [28–31], although it was effective in reducing total
blood loss after paediatric cardiac surgery [32]. Higher costs
when using aprotinin make TXA a better option with simi-
lar efficacy. In this study, we clearly proved that the use of
TXA in surgical scoliotic cases greatly reduced the volume
of whole blood and blood from cell saver transfused back
to the patients, although no comparison on the use of other
antifibrinolytic agents were carried out because of the
standard and consistency of clinical practice.
Studies tried to look for the factors other than the use of
TXA affecting the total blood loss, however, no conclusion
Table 2 Comparisons on the clotting capabilities, haemoglobin change, blood products transfused, and total blood loss in patients
with or without using TXA
Surgical parameters Tranexamic acid P
TXA (N = 55) Control (N = 35)
Clotting capability
Pre-op PT 11.56 ± 0.87 11.32 ± 1.04 0.24
Pre-op INR 1.07 ± 0.07 1.05 ± 0.06 0.18
Pre-op APTT 37.24 ± 3.88 37.92 ± 4.83 0.46
Haemoglobin change
Latest postop – preop −2.99 ± 1.58 −3.33 ± 1.56 0.33
Equivalent volume of whole blood/packed red blood cell transfused
Intra-operative 472.50 ± 370.48 891.67 ± 358.35 0.04
Post-operative 150.00 ± 256.04 333.33 ± 516.40 0.45
Volume of cell saver blood transfused back to patient (ml) 575.36 ± 412.25 1684.26 ± 1233.91 <0.01
Volume of platelet transfused (ml) 194.41 ± 125.19 219.28 ± 144.17 0.59
Volume of fresh frozen plasma (FFP) transfused (ml) 798.86 ± 520.00 863.18 ± 458.48 0.67
Latest post-operative hemoglobin level 10.00 ± 1.18 9.66 ± 0.75 0.34
Number of days for hemoglobin level reaching stable level post-operatively 4.39 ± 2.12 4.23 ± 1.69 0.80
Total blood loss by anesthetist estimation (ml) 1826.11 ± 1081.45 3889.60 ± 2440.80 <0.01
Total blood loss per segment (ml/segment) 135.62 ± 78.10 328.44 ± 222.68 <0.01
TXA tranexamic acid used, Control none used, PT prothrombin time, INR international normalised ratio, APTT activated partial thromboplastin time
Table 3 Sensitivity analysis on different linear regression models on the use of tranexamic acid, infusion of coagulation factors, and
clotting capability on the total blood loss controlled for confounding factors





















1 ✓ ✓ ✓ ✓ ✓ ✓ 0.31 −4.98 <0.01
2 ✓ ✓ ✓ ✓ ✓ ✓ ✓ 0.45 −5.25 <0.01
3 ✓ ✓ ✓ ✓ ✓ ✓ ✓ 0.44 −5.25 0.05
4 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 0.27 −3.99 0.14
5 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 0.32 −5.26 <0.01
6 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 0.46 −5.25 <0.01
7 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 0.48 −4.93 0.10
8 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 0.39 −4.01 0.15
TXA, use of tranexamic acid (Yes/No), FFP fresh frozen plasma, PT prothrombin time, INR international normalised ratio, APTT activated partial thromboplastin time
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has been clearly made probably as a result of limited data
collected for data analysis. Discussions on autologous blood
transfusion and reinfusion of salvaged blood from cell saver
machine being the causative factor have been introduced
for over a decade [6, 20, 25]. Transfusion requirements and
coagulation parameters were first introduced by Sethna
et al. in a study with 44 children and adolescents undergo-
ing scoliotic surgical corrections through comparative ana-
lyses [5]. Other factors like age, gender, and number of
vertebral levels fused, were introduced in recent publica-
tions [20, 25]. Length of hospital stay was discussed in a
couple of reports, while this was the secondary clinical
outcome of the use of TXA instead of being a factor on
controlling total blood loss [33, 34]. At the ever-vigorous
surgical environment, there are many factors which can
affect the total blood loss, not solely dictated by the use of
TXA, and these have to be controlled for us to draw a con-
clusion on the effect of TXA on controlling blood loss at
surgery. This study collected information in possible con-
founding factors on total blood loss with the use of TXA at
surgery in Chinese AIS patients, and confirmed the efficacy
of TXA after controlling major confounding factors.
In this study, total blood loss estimated by anaesthesia
technician was significantly reduced in patients using TXA
at surgery. At the same time, volume of blood transfused
from cell saver was also much reduced in TXA group. A re-
cent study on the use of TXA in 49 surgical AIS patients
undergoing posterior spinal fusion by a single surgeon
showed similar findings on great decrease in total blood
loss as of the present study [20]. The volume of blood
transfused, however, did not appear to be affected [20]. In
this study, the volume of salvaged blood from cell saver was
much decreased in TXA group. Nonetheless, the total
amount of blood loss and cell saver blood returned to the
patients were relatively huge. These were because the spinal
curvatures were large and the fusion levels were high. Simi-
lar results were obtained from surgeries on severe curva-
tures [19, 33]. In summary. we have established a very tight
transfusion protocol for AIS surgery, which makes the re-
sults different from the study from Lykissas and colleagues
[20]. A recent randomized control trial was carried out to
look for the efficacy of different antifibrinolytics in AIS.
TXA and epsilon-aminocaproic acid effectively reduced es-
timated and actual blood loss, as well as declined in haem-
atocrit after surgery compared with saline solution [25].
The present study also gives us an idea on the rate of
blood loss decrease after using TXA at surgery with proper
adjustment of confounding factors. Regarding to the trans-
fusion rate being another important parameter evaluating
the efficacy of antifibrinolytics, authors, the factors affecting
the transfusion rate is mainly a surgeon-decisive issue,
namely patient comorbidities, patient preference, preopera-
tive blood donation, and clinical judgment [25]. Similar
findings were found in another RCT published in Cochrane
Library [35]. A systematic review and meta-analysis on the
use of intravenous TXA in spinal surgery carried out in
China showed much reduced volume of blood loss and vol-
ume of transfused packed cells, although patient age was
one of the study exclusion criteria making the analyses not
totally applicable to present study [26]. An extended multi-
centre review on the use of different antifibrinolytic agents
to reduce blood loss during vertebral column resection in
paediatrics also confirmed the effectiveness of reduced esti-
mated blood loss when using TXA during surgery after
normalized to patient size and levels excised [19]. Similar
observations are well-documented in many previous studies
[5, 6, 15, 16, 18, 19, 33–39]. The present study is the first
study on the evaluation of efficacy of TXA in Chinese AIS
patients, with the novel findings of factors affecting total
blood loss.
This is the first report on the use of TXA in surgical
Chinese AIS patients. The factors affecting the total
blood loss are derived by a series of sensitivity analysis
through different regression models with the proper
controlling of confounding factors.
Limitations
There are limitations we have to consider in this study.
The small sample size and retrospective nature of this
comparative study would limit the data generalizability.
Our surgeons and anaesthetists had many years of experi-
ence in spinal surgery before beginning of this study, the
ever-improving surgical skills over the years could influ-
ence the amount of total blood loss. The concern on the
effect of the improvement of surgical skills on the amount
of total blood loss was proven minimal after a closed mon-
itoring of difference of total surgical blood loss over the
study period. Yet a prospective dose-ranging study is still
required to determine the optimal dose for spine surgery
on patients with idiopathic scoliosis. To provide additional
information on the efficacy and safety of TXA, multi-
centre randomized prospective analysis in the future is
warranted.
Conclusions
Patients undergoing posterior spinal corrective surgery
with the use of TXA showed much reduced total blood
loss, reduced use of transfused blood, and much less cell
saver blood transfused back to the patient. Using TXA at
surgery, the total blood loss was decreased by 794.3 ml
after controlling for maximum major curve and other
clinical factors, clotting capabilities, and infusion of coagu-
lation factor. Use of tranexamic acid significantly re-
duced total surgical blood loss over corrective surgery
for severe AIS patients, after adjusting for possible con-
founding factors, clotting capabilities, and infusion of
coagulation factors.
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